RNA Biomarker Detection Methods
By detecting RNA biomarkers, the method addresses the challenge of determining effective doses for HDAC6 inhibitors, enabling patient classification and treatment efficacy assessment.
Patent Information
- Application Number
- JP2024531107
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-23
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-19
AI Technical Summary
The development of selective HDAC6 inhibitors, such as N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide, faces challenges in determining pharmacologically active doses due to the lack of toxic side effects, making traditional dose escalation methods inadequate for clinical development.
A method involving the detection and quantification of RNA biomarkers, specifically the expression levels of genes such as CD84, RANK/TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204/MSR1, CD206/MRC1, MMP9, NBEAL2, LTBP4, ANXA6, FATP1/SLC27a1, ADA, CD276, and IRF6, is developed to assess the effective dose and biological activity of HDAC6 inhibitors in patients.
This method allows for the classification of patients as responsive or non-responsive to HDAC6 inhibitor treatment based on gene expression signatures, providing a reliable means to determine effective doses and treatment efficacy.
Smart Images

Figure 2024543138000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for detecting RNA biomarkers. [Background technology]
[0002] The genetic material of eukaryotic cells is organized in a complex and dynamic structure called chromatin, which is composed of DNA and proteins. The main protein components of chromatin are basic proteins called histones, which interact with DNA to organize the structural units of chromatin, nucleosomes, into the first level of chromosome compaction in the nucleus. The interaction of basic histone residues with the acidic phosphate backbone of DNA is crucial in determining the compaction of nucleosomes and the accessibility of molecular complexes that regulate replication and transcription. This interaction is primarily influenced by multiple post-translational modifications of the N-terminal sequences of core histones, including methylation, phosphorylation, ubiquitination, and acetylation. Deacetylation of histone N-terminal lysine residues allows the protonation of amine groups, which then acquire a positive charge and interact with the negative charges present in DNA. Such interactions result in a more compact state of chromatin, leading to the repression of gene expression.
[0003] Conversely, acetylation of this residue inhibits the formation of ionic bonds and results in a less compact chromatin structure, which increases the exposure of DNA and allows interactions with macromolecular complexes that activate gene transcription.
[0004] In addition to these physicochemical consequences, post-translationally modified residues are also specifically recognized by bromo- or chromodomain-containing "reader" proteins that recognize methylation or acetylation marks and are involved in stabilizing repressed or activated chromatin states.
[0005] The degree of histone acetylation is controlled by the balance of activity of two enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). Alterations in this delicate balance can lead to a loss of cellular homeostasis that is common in a variety of human diseases, including cancer, neurological disorders, inflammation, and autoimmune diseases.
[0006] Histone deacetylases are classified as enzymes that catalyze the deacetylation of amine groups on the N-terminal lysine residues of histones. This enzymatic activity on lysines in the histone tails has led to the classification of histone deacetylases as "erasers" in contrast to HAT enzymes, which are called "writers". As a result, a large number of substrates for these enzymes have been found, as they are also active on non-histone protein substrates that contain N-acetyl-lysine, a substrate for HAT enzymes. These substrates include transcriptional regulators, DNA repair enzymes, and many other nuclear and cytoplasmic proteins.
[0007] The human HDAC family consists of 18 enzymes and is divided into two groups: Zn-dependent HDACs and NAD-dependent HDACs, also known as sirtuins (class III). Zinc-dependent HDACs are further classified into four classes: 1) class I, which includes HDAC1, 2, 3, and 8, which are ubiquitous isozymes that are primarily located in the nucleus; 2) class IIa, which includes HDAC4, 5, 7, and 9, which are both nuclear and cytoplasmic isozymes; 3) class IIb, which includes HDAC6 and HDAC10, which are primarily located in the cytoplasm; and 4) class IV, which includes only HDAC11. Unlike class I HDACs, class IIa and to some extent class IIb have tissue-specific expression.
[0008] It is clear that these enzymes are involved in a myriad of cellular functions by controlling gene expression and acting on histones and transcription factors, and in addition, by acting on many protein substrates, they are involved in many other processes such as signal transduction and cytoskeletal rearrangements.
[0009] Over the past two decades, several HDAC inhibitors have been developed, and five molecules (vorinostat, romidepsin, belinostat, panobinostat, and chidamide) have been approved for the treatment of cancer in humans. All of these molecules inhibit multiple HDAC subtypes that also play a role in normal tissues. As such, their therapeutic potential is limited by toxicities such as thrombocytopenia, gastrointestinal toxicity, and fatigue.
[0010] Therefore, the interest of the scientific community has focused on the synthesis and study of selective inhibitors against individual HDAC isoforms, aiming to develop molecules with better pharmacological potency.
[0011] Selective inhibitors against certain HDAC isoforms, especially HDAC6, may be particularly useful for the treatment of pathologies associated with proliferation disorders and protein accumulation, immune system disorders, respiratory diseases, neurological diseases, and neurodegenerative diseases, such as stroke, Huntington's disease, ALS, and Alzheimer's disease. HDAC6 is a member of the Zn-dependent histone deacetylase family and has several unique and distinguishing features, such as the presence of two active sites with different catalytic activities and possibly different biological roles. Substrates of HDAC6 include α-tubulin, Hsp90 (heat shock protein 90), cortactin, and β-catenin.
[0012] Regulation of the acetylation status of these proteins by HDAC6 has been correlated with several important processes, such as immune response (Wang et al., Nat. Drug Disc. (2009), 8(12), 969-981 (Non-Patent Document 1); Kalin JH et al., J. Med. Chem. (2012), 55, 639-651 (Non-Patent Document 2); de Zoeten EF et al., Mol. Cell. Biol. (2011), 31(10), 2066-2078 (Non-Patent Document 3)), control of microtubule dynamics, including cell migration and cell-cell interactions (Aldana-Masangkay et al., J. Biomed. Biotechnol. (2011), ID 875824 (Non-Patent Document 4)), and degradation of misfolded proteins. HDAC6 is constitutively expressed in the majority of living tissues and has a widespread cytosolic localization, although it also exerts activity in the nuclear compartment. HDAC6 activity is altered in pathologies such as cancer, neurological disorders, respiratory disorders, and autoimmune diseases (Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., and Yang, J. (2018); “Histone deacetylase 6 in cancer.” Journal of Hematology & Oncology 11, 111 (Non-Patent Document 5); Prior, R., Van Helleputte, L., Klingl, YE, and Van Den Bosch, L. (2018), “HDAC6 as a potential therapeutic target for peripheral nerve disorders.” Expert Opinion on Therapeutic Targets 22, 993-1007 (Non-Patent Document 6)).
[0013] In the context of cancer, HDAC6 has been recognized as a key regulator of the function of the tumor microenvironment, controlling antitumor immune responses by regulating the expression of PD-L1 in immune cells and tumor cells. HDAC6 is also involved in regulating the expression of oncoproteins, especially in hematological tumors, such as various types of leukemia (Fiskus et al., Blood (2008), 112(7), 2896-2905 (Non-Patent Document 7); Rodriguez-Gonzales, Blood (2008), 112(11), abstract 1923 (Non-Patent Document 8)) and multiple myeloma (Hideshima et al., Proc. Natl. Acad. Sci. USA (2005), 102(24), 8567-8572 (Non-Patent Document 9)). The regulation of α-tubulin acetylation by HDAC6 may be involved in the initiation of metastasis, in which cell motility plays an important role (Sakamoto et al., J. Biomed. Biotechnol. (2011), 875824 (Non-Patent Document 10)).
[0014] Moreover, in stark contrast to preclinical and clinical observations made with non-selective HDAC inhibitors, which suffer from dose-limiting toxicity, HDAC6 inhibitors do not show any obvious signs of toxicity, and HDAC6 knockout mice are viable, develop normally, and show no obvious signs of pathological changes, in contrast to what is observed upon loss of expression of other HDAC subtypes.
[0015] In conclusion, selective inhibitors of HDAC6 are expected to have considerable therapeutic potential while at the same time being very well tolerated.
[0016] International Patent Application Publication No. 2018 / 189340 (WO2018 / 189340 (Patent Document 1)) discloses a particularly effective HDAC6 inhibitor, N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide, which has been found to have significant activity in modulating antitumor immune responses. In line with the known good tolerability of HDAC6 inhibitors, the molecule is well tolerated (1000 mg / kg) in rats, mice and dogs, suggesting that it may also be well tolerated in humans.
[0017] This hypothesis is further supported by clinical data obtained with the HDAC6 inhibitors, ricorinostat and KA2507, which were very well tolerated in patients (Amengual JE et al., Oncologist (2021) 3:184-e366 (Non-Patent Document 11); Tsimberidou AM et al., Clin Cancer Res (2021) 27:3584-3594 (Non-Patent Document 12)).
[0018] However, while highly desirable for a drug, the absence of toxic side effects poses a challenge to its clinical development.
[0019] Traditionally, in oncology phase I clinical protocols, dose escalation is planned until the maximum tolerated dose is reached. Cohorts are usually expanded at this dose level, and the recommended phase II dose is derived from information on tolerability, PK, and early signs of efficacy. In the absence of any toxic side effects, other parameters need to be used to determine the dose.
[0020] Biomarkers are extremely useful in determining the biologically effective dose.
[0021] US Patent Application Publication No. 2012 / 176076 (US2012 / 176076 (Patent Document 2)) discloses a kit for determining the therapeutic effect of a histone deacetylase 6 inhibitor (HDAC6) in a subject with multiple myeloma, the kit comprising a detection agent that specifically binds to an HDAC6 biomarker RNA selected from miRNA (SEQ ID NO: 1-23), mRNA (SEQ ID NO: 24-25) and small non-coding RNA (SEQ ID NO: 26-27). The only mRNA sequences encoding proteins are SEQ ID NO: 24, which corresponds to Homo sapiens hypoxia-inducible factor 1 subunit alpha (HIF1A), transcript variant 2 mRNA, and SEQ ID NO: 25, which corresponds to Homo sapiens protein tyrosine phosphatase receptor type U (PTPRU), transcript variant 2 mRNA.
[0022] For HDAC6 inhibitors, increased tubulin acetylation levels can be used as a readout. For example, patients who receive a given dose of HDAC6 inhibitor can have blood drawn at different time points after drug administration and acetyl tubulin in PBMCs can be measured using Western blot analysis. Although relatively straightforward, this method is qualitative or semi-quantitative and measures a pharmacodynamic marker that is not directly related to antitumor activity. [Prior art documents] [Patent documents]
[0023] [Patent Document 1] International Patent Application Publication No. 2018 / 189340 [Patent Document 2] US Patent Application Publication No. 2012 / 176076 [Non-patent literature]
[0024] [Non-Patent Document 1] Wang et al, Nat. Drug Disc. (2009), 8(12), 969-981 [Non-Patent Document 2] Kalin JH, et al., J. Med. Chem. (2012), 55, 639-651 [Non-licensed document 3] de Zoeten EF, et al., Mol. Cell. Biol. (2011), 31(10), 2066-2078
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
Non-licensed Document 8
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
Non-licensed Document 15
Non-licensed Document 16
Non-licensed Document 17
Non-licensed Document 18
Non-licensed Document 19
Non-licensed Document 20
Non-licensed Document 21
[0025] Therefore, there is a need for quantitative methods based on biological markers that can be assessed in patient samples that can be used to assess pharmacologically active doses of HDAC6 inhibitors, particularly N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide. [Brief description of the drawings]
[0026] [Figure 1] FIG. 1 shows a scheme of the experimental procedures performed to obtain gene expression data by RNAseq. [Figure 2A] FIG. 1 shows inter-sample distance analysis. [Figure 2B] FIG. 1 shows a principal component analysis. [Figure 3A] Venn diagram showing the number of genes selectively or commonly upregulated by a particular treatment. Created with the Venny tool, an interactive tool for comparing lists using Venn diagrams, Oliveros, JC (2007-2015) (https: / / bioinfogp.cnb.csic.es / tools / venny / index.html). [Figure 3B] Venn diagram showing the number of genes selectively or commonly upregulated by a particular treatment. Created with the Venny tool, an interactive tool for comparing lists using Venn diagrams, Oliveros, JC (2007-2015) (https: / / bioinfogp.cnb.csic.es / tools / venny / index.html). [Figure 4]Purified human monocytes were treated as indicated and analyzed for CD274 / PD-L1 expression from RNAseq data. [Figure 5A] FIG. 1 shows that ITF3756 treatment downregulated CD84 expression in human monocytes. [Figure 5B] FIG. 1 shows the schematic structure of CD84. [Figure 5C] FIG. 1 shows immune cell expression. [Figure 6] FIG. 1 shows that ITF3756 induces potent downregulation of RANK / TNFRSF11a similar to TNF-α. [Figure 7A] FIG. 1 shows that ITF3756 reduced the expression of CXCL2 in human monocytes. [Figure 7B] FIG. 1 shows that ITF3756 reduced the expression of CXCL3 in human monocytes. [Figure 8] FIG. 1 shows that ITF3756, alone and in combination with TNF-α, strongly reduced STAB1 gene expression. [Figure 9] FIG. 1 shows that ITF3756, alone and in combination with TNF-α, increased the expression of NBEAL2. [Figure 10] FIG. 1 shows that ITF3756 upregulates the expression of LTBP4. [Figure 11] FIG. 1 shows the effect of ITF3756 on FATP1 / SLC27A1 expression in human monocytes, and the opposing effects of ITF3756 and TNF-α on FATP1 / SLC27A1 expression. [Figure 12] FIG. 1 shows that ITF3756 alone induced regulation of IRF6 expression, while TNF-α or the combination had no effect. [Figure 13] FIG. 1 shows that ITF3756 upregulated the expression of the ANXA6 gene alone or in the presence of TNF-α in a clearly synergistic manner. [Figure 14]FIG. 1 shows that ITF3756 upregulates CD40 gene expression and, when combined with TNF-α, slightly increases the upregulation of CD40 expression induced by TNF-α alone. [Figure 15] FIG. 1 shows that the M2 macrophage marker CD163 was downregulated with ITF3756 alone and in the presence of TNF-α. [Figure 16] FIG. 1 shows that the M2 macrophage marker CD204 / MSR1 was downregulated by ITF3756 alone and strongly downregulated in the presence of TNF-α. [Figure 17] FIG. 1 shows that the M2 macrophage marker CD206 / MRC1 was strongly downregulated by ITF3756 alone and in the presence of TNF-α. [Figure 18] FIG. 1 shows that the M2 macrophage marker MMP9 was downregulated by ITF3756. No regulation was observed when cells were treated with TNF-α or ITF3756 and TNF-α compared to untreated controls. [Figure 19] Figure 2 shows that the M2 macrophage marker ADA was downregulated by ITF3756.Figure 3 shows that TNF-α and its combination induces upregulation of ADA gene expression. [Figure 20A] FIG. 1 shows downregulation of STAB1 gene in PBMCs treated with 1 μM ITF3756. [Figure 20B] FIG. 1 shows upregulation of IRF6 gene in PBMCs treated with 1 μM ITF3756. [Figure 21A] FIG. 1 shows that ITF3756 induces sustained tubulin acetylation in vivo. Western blot showing acetyl-tubulin and tubulin bands. [Figure 21B]FIG. 1 shows that ITF3756 induces sustained tubulin acetylation in vivo. Band intensities were quantified and the fold increase in tubulin acetylation normalized to total tubulin content was calculated. [Figure 22A] Figure 1 shows that tumor-bearing animals respond differently to ITF3756 treatment: animals treated with ITF3756 can be classified into three different groups. Figure 2 shows ITF3756 group compared to vehicle group (mean tumor volume ± SEM). [Figure 22B] Figure 1 shows that tumor-bearing animals respond differently to ITF3756 treatment: animals treated with ITF3756 can be classified into three different groups. Figure 2 shows the variation of tumor volume in a single animal during the study in four exemplary groups. [Figure 22C] Figure 1 shows that tumor-bearing animals respond differently to ITF3756 treatment: animals treated with ITF3756 can be classified into three different groups. Figure 2 shows the variation of tumor volume in a single animal during the study in four exemplary groups. [Figure 22D] Figure 1 shows that tumor-bearing animals respond differently to ITF3756 treatment: animals treated with ITF3756 can be classified into three different groups. Figure 2 shows the variation of tumor volume in a single animal during the study in four exemplary groups. [Figure 22E] Figure 1 shows that tumor-bearing animals respond differently to ITF3756 treatment: animals treated with ITF3756 can be classified into three different groups. Figure 2 shows the variation of tumor volume in a single animal during the study in four exemplary groups. [Figure 23A] Figure 1 shows that tumor-bearing animals respond differently to anti-PD-1 treatment, and animals treated with anti-PD-1 can be classified into three different groups. Figure 2 shows anti-PD-1 groups (mean tumor volume ± SEM) compared to vehicle and isotype control groups. [Figure 23B]Figure 1 shows that tumor-bearing animals respond differently to anti-PD-1 treatment: animals treated with anti-PD-1 can be classified into three different groups. Figure 2 shows the variation of tumor volume in a single animal during the study in four exemplary groups. [Figure 23C] Figure 1 shows that tumor-bearing animals respond differently to anti-PD-1 treatment: animals treated with anti-PD-1 can be classified into three different groups. Figure 2 shows the variation of tumor volume in a single animal during the study in four exemplary groups. [Figure 23D] Figure 1 shows that tumor-bearing animals respond differently to anti-PD-1 treatment: animals treated with anti-PD-1 can be classified into three different groups. Figure 2 shows the variation of tumor volume in a single animal during the study in four exemplary groups. [Figure 23E] Figure 1 shows that tumor-bearing animals respond differently to anti-PD-1 treatment: animals treated with anti-PD-1 can be classified into three different groups. Figure 2 shows the variation of tumor volume in a single animal during the study in four exemplary groups. [Figure 24A] Figure 1 shows correlation of MMP9 downregulation in the tumor microenvironment by responder mice, showing that when considering all animals, there was no correlation showing a statistically significant decrease in MMP9 expression compared to non-responders. [Figure 24B] Figure 1 shows the correlation of MMP9 downregulation in the tumor microenvironment by responder mice, showing that CT26-bearing mice treated with ITF3756 had a statistically significant decrease in MMP9 expression compared to non-responders. [Figure 24C] Figure 1 shows correlation of MMP9 downregulation in the tumor microenvironment by responder mice, showing that when considering animals treated with anti-PD-1, there was no correlation showing a statistically significant decrease in MMP9 expression compared to non-responders. [Figure 25A]FIG. 1 shows correlation of upregulation of IRF6 in the tumor microenvironment by responder mice, showing that there was no upregulation of IRF6 expression in comparison to non-responders when considering all animals. [Figure 25B] Figure 1 shows correlation of upregulation of IRF6 in the tumor microenvironment by responder mice.Compared to non-responders, responder mice treated with ITF3756 show a significant upregulation of IRF6 expression. [Figure 25C] Figure 1 shows correlation of upregulation of IRF6 in the tumor microenvironment by responder mice, showing that when considering animals treated with anti-PD-1, there was no correlation showing upregulation of IRF6 expression in comparison to non-responders. [Figure 26A] FIG. 1 shows correlation of upregulation of CD40 in the tumor microenvironment by responder mice, showing that when considering all animals, there was no correlation showing upregulation of CD40 expression in comparison to non-responders. [Figure 26B] Figure 1 shows correlation of CD40 upregulation in the tumor microenvironment by responder mice: In comparison to non-responders, responder mice treated with ITF3756 show a statistically significant upregulation of CD40 expression. [Figure 26C] Figure 1 shows correlation of upregulation of CD40 in the tumor microenvironment by responder mice, showing that when considering animals treated with anti-PD-1, there was no correlation showing upregulation of CD40 expression in comparison to non-responders. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] (definition) Unless otherwise defined, all technical terms, expressions and other scientific terms used herein are intended to have the meaning commonly understood by those having ordinary skill in the art to which this disclosure belongs.In some cases, terms with commonly understood meanings are defined herein for clarity and / or ready reference.Therefore, their definitions in this specification should not be interpreted as representing substantial differences beyond the meaning commonly understood in the art.
[0028] The terms "comprising," "having," "including," and "containing" should be understood as open-ended terms (meaning "including, but not limited to") and should be considered as support for terms such as "essentially consist of," "essentially consisting of," "consist of," or "consisting of."
[0029] The terms "essentially consist of" and "essentially consisting of" should be understood as semi-close-end terms meaning that no other ingredients that affect the novel properties of the invention are included (and therefore may include any excipients).
[0030] The terms "consist of" and "consisting of" are to be understood as closed-ended terms.
[0031] As used herein, the term "gene expression signature" refers to an expression pattern derived from a combination of several mRNAs or RNAs (i.e., transcripts) that are used as biomarkers.
[0032] According to the present invention, the term "expression level of an RNA biomarker" refers to the detection and / or quantification of RNA or mRNA of a particular gene (biomarker), for example, determining and / or quantifying over- or under-expression of an RNA or mRNA in comparison to a control, determining the presence or absence of an RNA or mRNA in a sample, determining the sequence of the RNA, determining any modification of the RNA, or detecting any mutation or alteration of the RNA. The RNA level can be determined by presence or absence, more or less than a control, or by obtaining a numerical value for the amount of RNA, such as copies of RNA per microliter. The expression level of an RNA can be quantified by absolute or relative quantification. Absolute quantification can be achieved by including a known concentration of one or more target nucleic acids and by referencing the hybridization intensity of the known target nucleic acid and the unknown nucleic acid (e.g., through the construction of a standard curve). Alternatively, relative quantification can be performed by comparing hybridization signals between two or more genes or between treated / untreated to quantify changes in hybridization intensity.
[0033] As used herein, the term "biomarker" (short for biological marker) refers to a biological indicator (eg, a transcript, i.e., mRNA) and / or measurement of some biological state or condition.
[0034] According to the present invention, a patient suffering from cancer is "responsive" to a therapeutic agent if contact with the therapeutic agent results in inhibition of tumor size or rate of cancer growth compared to growth in the absence of contact with the therapeutic agent. Cancer growth can be measured in a variety of ways, for example by measuring tumor size or expression of tumor markers appropriate to the tumor type.
[0035] A patient suffering from cancer is "non-responsive" to a therapeutic agent if, as a result of contact with the therapeutic agent, tumor size or the rate of cancer growth is not inhibited, or is inhibited to a very low extent, compared to growth in the absence of contact with the therapeutic agent. As discussed above, cancer growth can be measured in a variety of ways, such as, for example, by measuring tumor size or the expression of tumor markers appropriate for that tumor type.
[0036] The characteristics of being unresponsive to a therapeutic agent are highly variable, with different cancers exhibiting different levels of "unresponsiveness" to a given therapeutic agent under different conditions. Furthermore, the measure of unresponsiveness can be assessed using additional criteria other than tumor growth size, such as, but not limited to, the patient's quality of life and the extent of metastasis.
[0037] According to the present invention, the terms "up-regulation", "up-regulated", "overexpression", and any variations thereof, are used interchangeably and refer to a value or level of a biomarker in a biological sample that is greater than the value or level (or range of values or levels) of the biomarker typically detected in a similar biological sample from a healthy or normal individual. The terms may also refer to a value or level of a biomarker in a biological sample that is greater than the value or level (or range of values or levels) of the biomarker that can be detected at different stages of a particular disease.
[0038] According to the present invention, the terms "down-regulation", "down-regulated", "under-expression", "under-expressed" and variations thereof are used interchangeably and refer to a value or level of a biomarker in a biological sample that is lower than the value or level (or range of values or levels) of the biomarker that is normally detected in a similar biological sample from a healthy or normal individual. The terms may also refer to a value or level of a biomarker in a biological sample that is lower than the value or level (or range of values or levels) of the biomarker that can be detected at different stages of a particular disease.
[0039] Furthermore, a biomarker that is either over-expressed or under-expressed may also be referred to as a "differential expression" or a "differential level" or a "differential value" as compared to a "normal" expression level or value of the biomarker that is indicative of a normal process or the absence of a disease or other condition in an individual. Thus, the "differential expression" of a biomarker may also be referred to as a variation from the "normal" expression level of the biomarker.
[0040] According to the present invention, the term "biological activity" of an HDAC6 inhibitor refers to the modulation / alteration of the expression of any of the genes described in the present invention.
[0041] According to the present invention, the term "efficacious dose" refers to the administration of an HDAC6 inhibitor that is believed to be effective in treating cancer in a patient.
[0042] DISCLOSURE OF THEINVENTION Surprisingly, we found that our selective HDAC6 inhibitor, N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide (also called ITF3756), is able to up- and / or down-regulate the expression of different genes in myeloid cells activated by pro-inflammatory stimuli, and has a broader effect on gene expression in both unstimulated and TNF-α-treated human monocytes.
[0043] Notably, we observed that TNF-α-stimulated human monocytes strongly upregulated the PD-L1 gene, and that PD-L1 surface expression and this upregulation were inhibited by ITF3756.
[0044] Furthermore, in vitro data reported in the experimental section illustrate that treatment of human monocytes with ITF3756 upregulates the expression of NBEAL2, FATP1 / SCL27A1, LTBP4, CD40, ANXA6 and IRF6 genes and downregulates the expression of CD84, CD276, RANK / TNFRSF11a, CXCL2, CXCL3, CD163, CD204 / MSR1, CD206 / MRC1, ADA, MMP9 and STAB1 genes.
[0045] The results obtained by the inventors therefore lead to the identification of a gene panel (also called "gene expression signature") that can be directly regulated by HDAC6 inhibitors, more specifically by the ITF3756 molecule, and that can be used as a gene expression signature of primary importance for the clinical development of this class of molecules.
[0046] Furthermore, this data is confirmed by experimental data obtained in vivo, where a significant downregulation of the MMP9 gene and an upregulation of the IRF6 and CD40 genes were observed in animals with CT26, which correlated with responder animals in the ITF3656 treatment group, demonstrating that the expression levels of the aforementioned genes are strictly related to the effect of the HDAC6 inhibitor in treated animals.
[0047] Thus, one embodiment of the present invention comprises: a) determining in a biological sample the expression level of at least one RNA biomarker that is modulated by an HDAC6 inhibitor and is selected from the group consisting of CD84, RANK / TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204 / MSR1, CD206 / MRC1, MMP9, NBEAL2, LTBP4, ANXA6, FATP1 / SLC27a1, ADA, CD276, CD40 or IRF6 genes; b) comparing said expression level with an expression level of a reference sample; The present invention relates to a method for evaluating the effective dose and / or biological activity of an HDAC6 inhibitor, comprising:
[0048] According to a preferred embodiment, the method assesses the effective dose and / or biological activity of HDAC6 inhibitors during the clinical treatment of patients suffering from cancer.
[0049] In a further preferred embodiment, the method evaluates the effective dose and / or biological activity of HDAC6 inhibitors after clinical treatment of patients suffering from cancer, which may be useful for evaluating the condition of patients after treatment.
[0050] According to a further preferred embodiment, said method is an in vitro or ex vivo method.
[0051] Preferably, the reference sample is derived from a specimen from a healthy subject not treated with an HDAC inhibitor, a specimen from a subject suffering from cancer not treated with an HDAC inhibitor, or from a subject at the start of treatment with an HDAC inhibitor (t=0).
[0052] According to a preferred embodiment, said HDAC inhibitor is selected from tubacin, tubastatin, nexturastat, ACY-1215, ACY-738, ACY-1083, KA2507, T518, SW100 or N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide (ITF3756), preferably said HDAC inhibitor is the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide.
[0053] According to a preferred embodiment, the method of the present invention further comprises the step of c) classifying the subject as responsive or non-responsive to the clinical treatment.
[0054] Preferably, patients suffering from cancer are classified as responsive or non-responsive to clinical treatment based on whether the expression value of at least one RNA biomarker is above or below a threshold expression value.
[0055] In one exemplary embodiment, a sample expression value greater than the expression value threshold is indicative of a patient who will respond to anti-cancer treatment. In another exemplary embodiment, a sample expression value less than the expression value threshold is indicative of a patient who will not respond to anti-cancer treatment.
[0056] In another exemplary embodiment, the expression value of the sample is greater than the threshold expression value and indicates the patient is non-responsive to anti-cancer treatment.In another exemplary embodiment, the expression value of the sample is less than the threshold expression value and indicates the patient is responsive to anti-cancer treatment.For example, it is demonstrated in the examples that the downregulation of MMP9, the upregulation of IRF6 and CD40 are correlated with responder animals.
[0057] In a further exemplary embodiment, the sample expression value below the threshold expression value indicates that the patient has a cancer type that is non-responsive to HDAC6 inhibitors or is at risk of developing a non-responsive cancer type.In another exemplary embodiment, the sample expression value above the threshold expression value indicates that the patient has a cancer type that is responsive to HDAC6 inhibitors or is at risk of developing a responsive cancer type.In another exemplary embodiment, the sample expression score above the threshold score indicates that the patient has a cancer subtype with good clinical prognosis.In another exemplary embodiment, the sample expression score below the threshold score indicates that the patient has a cancer subtype with poor clinical prognosis.
[0058] According to a further preferred embodiment, in the method of the invention, the expression levels of the biomarkers NBEAL2, LTBP4, ANXA6, FATP1 / SCL27a1.CD40 or IRF6 are upregulated by HDAC6 inhibitors and the expression levels of the RNA biomarkers CD84, RANK / TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204 / MSR1, CD206 / MRC1, ADA, CD276 or MMP9 are downregulated by HDAC6 inhibitors.
[0059] According to a preferred embodiment, in the method of the invention, the expression levels of at least the RNA biomarkers STAB1, CD84, CD206 / MRC1, MMP9, CD163, CD40 and IRF6 are assessed, preferably the expression levels of at least the RNA biomarkers MMP9, CD40 and IRF6 are assessed.
[0060] According to further preferred embodiments, the aforementioned cancers are adrenocortical cell carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma of the skin, bladder cancer, brain tumor, breast cancer, cancer of unknown primary site, cardiac tumor, cervical cancer, bile duct cancer, colon cancer, endometrial cancer, esophageal cancer, intraocular melanoma, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, testicular cancer, head and neck cancer, hepatocellular carcinoma, islet cell tumor, pancreatic neuroendocrine tumor, Langerhans cell histiocytosis, leukemia, lung cancer (non-small cell, small cell, pleuroblastoma and tracheobronchial tumor), black lung cancer, pulmonary fibrosis ... Selected from chromoma, Merkel cell carcinoma, mesothelioma, midline duct carcinoma with NUT gene alteration, multiple endocrine neoplasia syndrome, multiple myeloma / plasma cell neoplasm, myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasm, neuroblastoma, ovarian cancer, pancreatic cancer, paraganglioma, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor, primary peritoneal cancer, prostate cancer, renal cell carcinoma, retinoblastoma, sarcoma, squamous cell carcinoma of the skin, thymoma and thymic carcinoma, thyroid cancer, renal pelvis and ureteral transitional cell carcinoma, uterine cancer, vaginal cancer, vascular tumors, vulvar cancer, and Wilms' tumor.
[0061] Preferably, the cancer is selected from melanoma, renal cell carcinoma, non-small cell lung cancer and colorectal cancer.
[0062] Preferably, the biological sample is a tissue sample or a body fluid, preferably said tissue sample is a tumor biopsy or blood cells, preferably said body fluid is blood, serum or plasma.
[0063] More preferably, said blood cells are monocytes or peripheral blood mononuclear cells (PBMCs).
[0064] According to the present invention, said monocytes may be isolated from a patient suffering from cancer or by in vitro plate cell culture of monocytes treated with HDAC6 inhibitors.
[0065] According to a preferred embodiment, the biomarker is an RNA transcript. As used herein, "RNA transcript" refers to both coding and non-coding RNA, including messenger RNA (mRNA), alternatively spliced mRNA, ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), and antisense RNA. Measurement of mRNA in a biological sample can be used as a surrogate for detecting the level of the corresponding protein and gene in the biological sample. Thus, any of the biomarkers or biomarker panels described herein can also be detected by detecting the appropriate RNA.
[0066] According to a preferred embodiment, the expression levels of the biomarkers in step a) are detected by RNA sequencing, quantitative RT-PCR (qRT-PCR), digital PCR, Affymetrix microarrays, custom microarrays or nanostring technology.
[0067] Methods for biomarker expression profiling include, but are not limited to, quantitative PCR, NGS, Northern blot, Southern blot, microarray, SAGE, or other techniques that can measure RNA, mRNA, or protein levels of a particular biomarker.
[0068] To correct for differences in the amount of starting material and variations in the efficiency of extraction and amplification reactions, global expression data for a given sample can be normalized using methods known to those of skill in the art.
[0069] According to a preferred embodiment, step a) of the method of the invention comprises the following substeps: (i) isolating PBMCs and / or monocytes; (ii) extracting an RNA sample; (iii) quantifying at least one RNA biomarker selected from CD84, RANK / TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204 / MSR1, CD40, CD206 / MCR1, MMP9, NBEAL2, LTBP4, ANXA6, FATP1 / SLC27a1, ADA, CD276, and IRF6 genes; (iv) evaluating differentially expressed biomarkers by bioinformatics analysis of the quantified RNA biomarkers; and (v) correlating the results obtained from point (iv) with responder or non-responder patients. The following will be implemented.
[0070] A further embodiment of the present invention is a kit for assessing the effective dose and / or biological activity of an HDAC6 inhibitor, comprising a multi-well plate and appropriate primers and / or probes for determining the expression level of each of the RNA biomarkers to be detected.
[0071] Preferably, the RNA biomarkers are selected from CD84, RANK / TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204 / MSR1, CD40, CD206 / MCR1, MMP9, NBEAL2, LTBP4, ANXA6, FATP1 / SLC27a1, ADA, CD276 and IRF6 genes.
[0072] A further preferred embodiment is a kit for use in assessing the effective dose and / or biological activity of an HDCA6 inhibitor, comprising a multi-well plate and suitable primers and / or probes for determining the expression level of at least one RNA biomarker selected from CD84, RANK / TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204 / MSR1, CD40, CD206 / MCR1, MMP9, NBEAL2, LTBP4, ANXA6, FATP1 / SLC27a1, ADA, CD276 and IRF6 genes. EXAMPLES
[0073] Materials and Methods (Monocyte purification and TNF-α activation) PBMCs used in the experiments were obtained from Buffy Coats of healthy donors (all samples were determined to be negative for transfusion-requiring infectious diseases) separated on Ficoll-Hypaque gradients (Biochrom).
[0074] Monocytes were isolated at 100 × 10 6 Monocytes were purified from human PBMCs by negative selection. Intact monocytes were isolated from human PBMCs using the Pan Monocyte Isolation Kit, and typical monocytes (CD14 ++ CD16 - ), atypical monocytes (CD14 + CD16 ++ ) and intermediate monocytes (CD14 ++ CD16 +() to achieve simultaneous enrichment of T cells, NK cells, B cells, dendritic cells, and basophils. Non-monocytes, such as T cells, NK cells, B cells, dendritic cells, and basophils, are indirectly magnetically labeled using a cocktail of biotin-conjugated antibodies and anti-biotin MicroBeads. Briefly, 400 μL of buffer (PBS 1X, 0,5% BSA, and 2 mM EDTA), 100 μL of FcR Blocking Reagent, and 100 μL of Biotin-Antibody Cocktail are added to PBMCs (pre-washed with PBS by centrifugation at 300 × g for 5 min), mixed and incubated for 5 min in a refrigerator (2 °C-8 °C). After incubation, 300 μL of buffer and 200 μL of anti-biotin MicroBeads are added to the cells, mixed and incubated for an additional 10 min in a refrigerator. After incubation, the cells were processed for subsequent magnetic cell separation. The cell suspension was applied onto the column and the flow-through containing unlabeled cells representing enriched monocytes was collected. Purified monocytes were washed with buffer by centrifugation at 300 × g for 5 min and counted in PBS. Purified monocytes (1.0 × 10 6 1 x 100 / ml) were pretreated with 1 μM ITF3756 or DMSO (0.005%) for 2 h in a final volume of 1 ml complete medium (RPMI (Biochrom), FCS 10%, and penicillin / streptomycin 1x (Sigma)) in 12-well plates. Cells were then stimulated or not with TNF-α (100 ng / mL, Peprotech) for 4 h. After incubation with ITF3756 and TNF-α, cells were collected, washed with PBS by centrifugation at 300 × g for 5 min, and stored at -80 °C.
[0075] Samples were thawed on the bench for 2 min and total RNA was extracted using Trizol reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. Briefly, Trizol reagent (5–10 × 10 60.75 ml Trizol per cell) was added to the samples and the samples were incubated at room temperature (RT) for 5 min. After incubation, chloroform (150 μL per 0.75 mL Trizol) was added and incubated at room temperature (RT) for 3 min before centrifuging the samples at 12000 × g and 4 °C for 14 min. After centrifugation, the mixture separated into three phases and the RNA remained in the aqueous phase. The aqueous phase for each sample was removed and placed in a new tube and isopropanol (0.375 mL per 0.75 mL Trizol) was added to each tube. The samples were incubated in the refrigerator (2-8 °C) for 30 min. The supernatant was removed and 75% ethanol (0.75 mL per 0.75 ml Trizol) was added. Centrifuged at 7500 × g and 4 °C for 5 min and the supernatant was discarded. The RNA was air-dried on the bench for 5-10 min. The RNA samples were then resuspended in water (10–50 μL).
[0076] RNA concentration was determined by measuring the absorbance at 260 nm using a NanoDrop 1000 spectrophotometer (Thermo Scientific). The absorbance at 280 nm can also be measured to estimate the degree of RNA contamination. The 260 nm / 280 nm absorbance ratio allows the identification of protein contamination. A 260 nm / 280 nm absorbance ratio of approximately 2 considered the sample to be sufficiently pure.
[0077] The integrity of the extracted RNA was assessed by capillary electrophoresis using an Agilent 2100 Bioanalyzer instrument (Agilent Technologies) with an Agilent RNA 6000 Pico kit (Agilent Technologies). This system allows for the simultaneous analysis of up to 12 samples using a high-purity RNA ladder of known concentration as a standard. The protocol includes denaturing all samples and the RNA ladder at 70 °C for 2 min and preparing the chip with a running gel (run gel) containing a fluorescent intercalator. The RNA molecules bind to the intercalator molecules and the fluorescence of the electrophoretically separated molecules is detected by the instrument.
[0078] The gel was prepared by pipetting 550 μL of RNA gel matrix into a spin filter (provided in the kit). After centrifugation at 1500×g for 10 min, a 65 μL aliquot of filtered gel was prepared. The RNA dye concentrate was equilibrated at RT for 30 min, vortexed, spun down, and 1 μL of dye was added to the 65 μL aliquot of filtered gel. The gel-dye mixture was mixed and centrifuged at 13000×g for 10 min. A new RNA chip was placed in the chip priming station and 9 μL of gel-dye mixture was pipetted into the assigned wells and distributed throughout the chip by the plunger. 5 μL of RNA marker was added to all 11 sample wells and the ladder well. Then, 1 μL of ladder in the ladder well and 1 μL of each sample in the 11 sample wells were added to the chip. The chip was vortexed at 2400 rpm for 1 min and run on the Agilent 2100 Bioanalyzer instrument within 5 min.
[0079] The software makes it possible to obtain an estimate of the purity of each sample by evaluating the RNA Quality Index (RQI), which is calculated based on an algorithm that assigns to each sample a value from 1 to 10 as a function of the rRNA 28S / rRNA 18S ratio. If this index is greater than or equal to 7.5, the sample is considered to be of high purity.
[0080] [RNAseq] A scheme of the experimental procedures performed to generate the RNA-seq data is shown in Figure 1.
[0081] (RNA extraction) To measure the quantity and integrity / purity of the RNA samples, a check control was first performed on an Agilent Technologies 2100 Bioanalyzer using the RNA 6000 LabChip® kit (Agilent#5067-1511). The Bioanalyzer is a bioanalytical device based on a combination of a microfluidic chip, voltage-induced size separation in gel-filled channels, and laser-induced fluorescence (LIF) detection on a miniaturized scale. The RNA Integrity Number (RIN) software algorithm can perform a grading of total RNA based on a numbering system from 1 to 10, where 1 is the most degraded and 10 is the most intact. All samples with an RIN below 7.5 were discarded, and the remaining samples were processed for library preparation and sequencing.
[0082] (PolyA mRNA selection) mRNA was isolated from 200 ng of total RNA using poly-T oligo-attached magnetic beads using two rounds of purification (positive selection) as suggested in the TruSeq RNA Sample Preparation manual (Illumina # 15015050).
[0083] (Library preparation and cDNA synthesis) Purified samples were processed using the TruSeq RNA-Seq v2 Library Preparation Kit. Briefly, chemical fragmentation was performed using divalent cations at elevated temperature in Illumina proprietary fragmentation buffer. First-strand cDNA synthesis was performed using random oligonucleotides and SuperScript II (Invitrogen# 18064-014). Subsequently, the second strand was performed using DNA polymerase I and RNase H. After Agencourt AMPure XP bead purification (Beckman# A63882), which allows size selection of fragments, overhangs were converted to blunt ends by exonuclease / polymerase activity and enzymes were removed. The 3' ends of DNA fragments were adenylated and ligated with Illumina TruSeq PE adapter-indexed oligonucleotides, double-purified, and selectively enriched in PCR reactions using Illumina PCR primer cocktails. PCR library products were purified with AMPure XP beads, qualitatively checked using the Agilent DNA 1000 assay (Agilent#5067-1504) on an Agilent 2100 Bioanalyzer, and quantified using a Qubit 2.0 Fluorometer with dsDNA Broad Range Assay kit (Thermo Fisher Scientific#Q32850). Indexed individual libraries were pooled to obtain equimolar concentrations of each sample and processed for cluster generation.
[0084] (Sequencing) Pooled libraries were loaded into single-end flow cells using a cBot system (Illumina) and TruSeq PE Cluster Generation kit v3 (Illumina # PE-401-3001). TruSeq technology supports massively parallel sequencing using a proprietary reversible termination site-based method5 (March 1, 2021), which allows for the detection of single bases incorporated into growing DNA strands. At the end of the run, approximately 30M of 75bp single-end reads were generated on a HiSeq2500 instrument (Illumina) using TruSeq SBS v3 reagents (Illumina # FC-401-3001). Finally, demultiplexed FASTQ files were generated following Illumina Pipeline data analysis.
[0085] (Bioinformatics Analysis) Single-end reads were trimmed of low-quality ends and adapters using TrimGalore http: / / www.bioinformatics.babraham.ac.uk / projects / trim_galore / (Non-Patent Document 13). Transcription abundance was estimated using Kallisto (Bray et al., 2016) (Non-Patent Document 14), and differentially expressed genes were identified using the DeSeq2 R package (Love et al., 2014) (Non-Patent Document 15) and an FDR-corrected p-value of <0.05.
[0086] (Quantitative real-time PCR) (material and method) (Test item)
[0087] [Table 1]
[0088] (Test sample working solution) Test articles were dissolved in DMSO and diluted into the appropriate medium to the required final concentration.
[0089] (Experimental Design) To expand the feasibility of the present invention, the potential of ITF3756 to regulate the mRNA expression of 17 genes was also tested in PBMCs. Gene expression was determined by comparing the expression of the above genes in treated and vehicle-treated cells.
[0090] (PBMC treatment with test product) 1×10 6 PBMCs were resuspended in RPMI 1640 medium (Dutch modification, ThermoFisher) at a density of cells / ml. Cells were plated in 6-well plates (Corning) at a volume of 3 ml per well. Cells were treated with ITF3576 at four concentrations (0.25, 0.5, 1 and 2 μM). For triplicate studies, each treatment concentration was replicated in three wells. Vehicle (DMSO 0.05%)-treated cells were also plated at the same density and volume. Plates were incubated at 37° C., 5% CO2 for 4 hours. At the end of the culture, cells were collected for total RNA extraction.
[0091] (RNA extraction and retro-transcription) After treatment with test compounds, PBMCs were removed from 6-well plates and collected in 15 ml tubes (Falcon). Wells were washed once with 1 mL PBS pH 7.4 (ThermoFisher) and the wash was added to the collected cell suspension. The cell suspension was centrifuged at 1500 rpm for 10 min. The supernatant was discarded and 350 μL of lysis buffer from the RNeasy Mini kit (Qiagen) was added to the cell pellet. The lysed cells were pipetted up and down 10 times to disperse cell debris. The RNA extraction procedure was then performed similar to the RNeasy Mini kit protocol, including the DNase step.
[0092] RNA concentration was determined using a Nano Drop 1000 spectrophotometer. RNA was diluted to 50ng / ul in a volume of 16μL with nuclease-free water (Ambion). Superscript VILO IV reagent (Invitrogen) was added to the RNA as shown below.
[0093] [Table 2]
[0094] Reverse transcription reactions were carried out in 96-well plates on an iCycler iQTM (Bio-Rad) using a thermal cycle of 10 min at 25° C., 10 min at 50° C., and 5 min at 85° C. 20 μL of the resulting cDNA was then diluted with 40 μL of TE buffer (Invitrogen) to a final theoretical concentration of 13.3 ng / μL.
[0095] (Detection of gene expression) TaqMan 20x Gene Expression Assay reagents (Applied Biosystems) were used to detect the gene transcripts, which are shown in Table 2.
[0096] [Table 3]
[0097] Real-time PCR was performed using a CFX C1000TM contact thermal cycler connected to a CFX 96 Touch Real time PCR detector system (Bio-Rad). qPCR reactions were performed in 96-well plates (Hard Shell PCR plates Bio-Rad) using Universal Master Mix reagents (Applied) containing AmpliTaq Gold® DNA Polymerase. 3 μL of cDNA corresponding to 40 ng of template was added to the PCR reaction reagents to a total volume of 15 μL as shown below:
[0098] For raw data collection, automated Excel reports reporting threshold cycle (Ct) values were exported and subsequently elaborated for calculation of expression modulation.
[0099] (Data Acquisition) The level of mRNA expression regulation was assessed by comparing the mRNA concentrations in treated and untreated samples. All data were normalized to the average expression signal of three housekeeping genes (reference genes: UBC, B2M, HPRT1) of the corresponding samples.
[0100] To determine the adjustability of the test item, -ΔΔCT " method was used.
[0101] For each treatment condition and each target, two replicates were run as single replicates. -ΔΔCT was calculated. -ΔΔCt = -(ΔCt,treated - ΔCt,untreated) ΔCt, treatment = Ct target treatment - Ct reference treatment ΔCt, untreated = Ct target untreated - Ct reference untreated Ct target untreated is intended to be the average of three untreated replicates. Ct standard treatment is intended to be the average of single replicates of three housekeeping genes. Ct measure untreated is intended to be the average of the Ct values of the three housekeeping genes for all untreated replicates. 1 less than 2 -ΔΔCT For treated samples showing values (downregulated), the untreated control -ΔΔCT value (corresponding to 1, no adjustment) and treated sample 2 -ΔΔCT Fold regulation values are reported as ratios between values, with a minus sign added to outline downregulation.
[0102] 2 -ΔΔCT Values greater than 1 indicate upregulation. Untreated control 2 -ΔΔCT value (corresponding to 1, no adjustment) and treated sample 2-ΔΔCT Fold-adjusted values were reported as ratios of the values.
[0103] (Computer Systems) The computer systems used to acquire and quantify data in this study included the following systems:
[0104] [Table 4]
[0105] (statistical analysis) All data are presented as mean ± standard deviation. All data are the mean of triplicate experiments. Statistical evaluation between groups (treated vs. untreated samples) was performed using a two-tailed Student's t-test.
[0106] In the graph, the threshold line corresponds to ±0.7 from the vehicle-treated control (1) (0.7 is three times the standard deviation (SD) of the fold change of the housekeeping gene for all samples).
[0107] ** P value < 0.05, * P value < 0.1.
[0108] (5. References) 1. Real-time quantitative PCR and 2 -ΔΔCT Analysis of relative gene expression data using the NMR method”, KJ Livak et al., Methods 25, 402-408 (2001) (Non-Patent Document 16).
[0109] (result) (RNAseq) After 4 h of monocyte incubation, RNAseq analysis identified numerous differentially expressed genes with padj<0.05 in ITF3756-treated samples, whereas treatment with TNF-α and the combination of ITF3756+TNF-α did not result in modulation with padj<0.05.
[0110] Table 3 shows the number of up- and down-regulated genes in each treatment sample and in the vehicle-treated control sample (don) in the indicated groups.
[0111] [Table 5]
[0112] Sample distance analysis and principal component analysis (Figure 2A and Figure 2B, respectively) showed that four different populations could be identified according to the treatment. This indicates clear differences in gene expression in the different populations and clustering of samples according to the treatment. Overall, both analyses show a homogenous response to the different treatments. This is surprising since different responses would be expected from different donors.
[0113] Next, we identified genes that were selectively up- or down-regulated by TNF-α, ITF3756, and ITF3756+TNF-α. Figures 3A and 3B show Venn diagrams of genes that were up- or down-regulated relative to the control, respectively.
[0114] This figure shows that there are 537 genes that are specifically upregulated by ITF3756, and 386 genes that are specifically downregulated by ITF3756. From these genes, we were particularly interested in these genes, since we were able to identify a specific signature for ITF3756.
[0115] We first analyzed the expression of PD-L1 (CD274) and confirmed its upregulation by TNF-α and inhibition by ITF3756. Figure 4 shows that ITF3756 induced a strong downregulation (59%) of PD-L1 gene expression in cells treated with TNF-α + ITF3756.
[0116] Next, we searched for genes that may affect the biological activity of ITF3756 among the up- or down-regulated genes. The selected genes are summarized in Table 4.
[0117] [Table 6]
[0118] As shown in Figure 5A, our experiments clearly show that ITF3756 strongly downregulates the expression of CD84. Human monocytes treated with 1 μM ITF3756 downregulate the expression of CD84, and this downregulation is further enhanced in the presence of proinflammatory stimuli such as TNF-α. Figure 5B and Figure 5C show the schematic structure of CD84 and the immune cell expression of CD84, respectively.
[0119] RANK (TNFRSF11A) and RANKL (TNFRSF11) are members of the TNF receptor superfamily. RANK can be expressed on various types of cells, including cancer cells, epithelial cells, and macrophages in the tumor microenvironment. Interaction with RANKL leads to tumor cell proliferation and cell migration, angiogenesis, macrophage recruitment, and M2 differentiation. ITF3756 induced a strong downregulation of RANK on monocytes (see Figure 6), suggesting a possible inhibition of M2 / protumor macrophage differentiation. This is consistent with our data showing an increase in M1 macrophages during in vitro differentiation in the presence of ITF3756. We also observe that treatment of cells with TNF-α and ITF3756 increases the downregulation of RANK / TNFRSF11a compared to treatment alone.
[0120] Chemokines are a group of chemoattractant cytokines that play an important role in cell migration from blood to tissues via venules and vice versa. CXCL2 and CXCL3 are two chemokines involved in the recruitment and generation of monocytic MDSCs, and their inhibition has been proposed to reduce mo-MDSC generation and improve host immunosurveillance (Shi et al., 2018). As shown in Figure 7A, ITF3756 reduces the expression of CXCL2 and restores the induction of upregulation by TNF, and normal levels of expression are established.
[0121] CXCL3 is another chemokine that influences the differentiation and function of human monocyte-derived dendritic cells, directing them towards a myeloid-derived suppressor cell (MDSC)-like phenotype. Moreover, MDSCs themselves express the CXCR2 receptor, which can be activated by CXCL3 to promote migration into the tumor microenvironment as described in KRAS-mutated colon cancer (Liao et al., (2019) Cancer Cell 35:559-572). As shown in Figure 7B, ITF3756 reduced the expression of this chemokine CXCL3.
[0122] The activity against these two chemokines, together with the effect on RANK expression, suggests that ITF3756 downregulates the expression of genes associated with a suppressor myeloid cell phenotype.
[0123] STAB1, also known as Clever-1 / Stabilin-1, is another key gene involved in the phenotypic change of macrophages and monocytes from an immunosuppressive to a proinflammatory phenotype. STAB1 is strongly downregulated by ITF3756 and synergistically decreased in the presence of TNF-α (Figure 8).
[0124] Among the genes upregulated by ITF3756, we selected NBEAL2, a BEACH domain-containing protein linked to granule growth (Figure 9), and LTBP4, a key regulator of transforming growth factor beta (TGFB1, TGFB2, TGFB3) that controls the activation of TGF-a by maintaining TGF-a in a latent state while stored in the extracellular space. The LTBP4 gene is downregulated two-fold by TNF-α (see Figure 10).
[0125] Our results show that ITF3756 counteracts this downregulation, but the effect is a restoration to normal levels in controls, without further upregulation.
[0126] Figure 11 shows the effect of ITF3756 on the expression of FATP1 / SLC27A1. This gene is involved in pro-inflammatory responses in macrophages (Nishiyama et al. (2018) International Immunopharmacology 55, 205-215 (Non-Patent Document 19)), making it a gene involved in a pro-inflammatory anti-tumor response potentially mediated by macrophages. ITF3756 shows an opposite effect on this gene compared to TNF-α, and treating cells with a combination of the two maintains the basal expression of the gene.
[0127] Another gene that may be involved in mediating pro-inflammatory effects in myeloid cells is interferon regulatory factor 6 (IRF6). IRF6 belongs to a family of nine transcription factors that share a highly conserved helix-turn-helix DNA-binding domain and a less conserved protein-binding domain. Most IRFs control the expression of interferons following viral infection. Other IRF members are also regulated by ITF3756, but IRF6 exerts a more potent change in gene expression.
[0128] FIG. 12 shows that only ITF3756 induced regulation of IRF6 expression, whereas TNF-α or the combination had no effect.
[0129] Annexin 6 (AnxA6) is another gene that shows robust upregulation upon ITF3756 treatment, and in the presence of TNF-α, the upregulation is even stronger and likely synergistic, as shown in Figure 13.
[0130] CD40 is a member of the TNF receptor superfamily and is expressed on various cell types, including monocytes / macrophages and dendritic cells. Binding of CD40 by its natural ligand, CD40L, results in the activation of T cells and the induction of antitumor macrophages. Several approaches have been made to activate the CD40-CD40L axis to induce antitumor immune responses, most recently the use of agonistic anti-CD40 antibodies. Biological effects and clinical responses have been observed below the MTD. Moreover, adverse events appear to be easily manageable in the clinical setting. The induction of CD40 gene expression obtained by ITF3756 (Figure 14) suggests that it may contribute to the general antitumor immune stimulation observed by this compound both in vitro and in vivo.
[0131] As shown in Table 3, many genes were regulated by ITF3756. Some of them have been identified as specific markers of tumor-associated macrophages (TAMs). Although the present analysis was performed on monocytes, the regulation of these genes may be related to the development of TAMs, the major innate immune cells that account for the majority (up to 50%) of the cell mass of human tumors. TAMs are highly heterogeneous and arise from tissue-specific resident macrophages and monocytes recruited from the circulation by chemoattractant gradients. Cancer type, stage, and intratumoral heterogeneity strongly influence the TAM population. The majority of TAMs are programmed by the tumor microenvironment to support primary tumor growth and metastasis. Nevertheless, the tumor microenvironment can influence TAMs and limit tumor growth and metastasis (Larionova et al., 2020). As shown in Table 5, tumor-promoting macrophages with M2 phenotype express specific markers, some of which were robustly downregulated in monocytes treated with ITF3756, supporting the possibility that they are involved in the induction of an antitumor phenotype when monocytes are recruited to tumor tissues.
[0132] [Table 7] Figure 8 (stabilin-1) and Figures 15 to 19 show the regulation of the genes in Table 5, including those effected by TNF-α and the combination of TNF-α+ITF3756.
[0133] ITF3756 exerts its gene regulatory activity in PBMCs Peripheral blood mononuclear cells can be isolated in a simpler and more rapid manner than monocytes, so we tested the gene regulatory activity of ITF3756 on this cell population using quantitative real-time PCR.
[0134] The results showed that the results obtained with this approach were consistent with those obtained with monocytes and RNAseq. Figure 20 shows the results obtained for two exemplary genes, STAB1 (Figure 20A) and IRF6 (Figure 20B), which were down-modulated and up-regulated by ITF3756, respectively.
[0135] (Ex vivo gene expression of transcripts in the tumor microenvironment identified IRF6, MMP9, and CD40 as biomarkers associated with antitumor response)
[0136] Materials and Methods (Animal husbandry) (Acclimatization) A minimum acclimation period of 14 days was allowed between receipt of the animals and the start of treatment to allow the animals to become accustomed to the laboratory environment.
[0137] (Housing) Mice were housed (4–5 mice / cage) in Makrolon cages (26.7 × 20.7 × h14 cm) with a grid-like iron cover and a bed of crushed, sterilized dust-free sawdust bedding. Food and water: Drinking water was available ad libitum. Each mouse was fed a complete pelleted mouse diet (4RF21, Mucedola) daily through the research facility.
[0138] (environmental conditions) Animals were housed under a light / dark cycle with constant temperature and humidity. Animal room parameters were assessed as follows: temperature 22 ± 2 °C, relative humidity 55 ± 10%, approximately 15–20 filtered air changes / hour, artificial light with a 12-h circadian cycle (7:00 AM–7:00 PM).
[0139] (Acclimatization) A minimum 14-day acclimation period was allowed between receipt of the animals and the start of treatment to allow the animals to become accustomed to the laboratory environment.
[0140] (ITF3756 (N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide) ITF3756 was synthesized at the Medicinal Chemistry Dept. of Italfarmaco SpA. Powdered batch 8 ITF3756 was dissolved in DMSO and stored at -20°C.
[0141] (Pharmacological Treatment)
[0142] [Table 8]
[0143] [Table 9]
[0144] [Table 10]
[0145] (Research design) 1 × 10 6 CT26 tumor cells (diluted to 100 μL in phosphate-buffered saline) were injected subcutaneously (s.c.) until the tumor volume was 75–100 mm 3 At the time of reaching 100% CI, the patients were treated with anti-PD1 or ITF3756 and the regulation of genes in the tumor microenvironment was examined by RNAseq. Since ITF3756 acts on the PD-1 / PD-L1 axis, this approach allows the identification of genes specific and common to both treatments. The overall schedule is shown in Table 9.
[0146] [Table 11]
[0147] (Immunoblot analysis) Mouse spleens were lysed in Triton buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 50 mM NaF, 1 mM EDTA pH 8, 0.1% Triton) supplemented with protease and phosphatase inhibitors (Roche, Germany) to obtain total cell extracts. Proteins were separated by SDS-PAGE, transferred to PVDF membranes and blocked with PBS-T (phosphate-buffered saline and 0.1% Tween-20 containing 5% nonfat dry milk) for 1 h at room temperature (RT). Incubation with primary antibodies was performed for 2 h at room temperature, followed by incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies. Detection was performed with ECL Western Blot Reagent (Amerscham). The antibodies used were mouse anti-acetylated tubulin (Sigma, T6793), mouse anti-tubulin (Sigma, T6074), and goat anti-mouse IgG(H+L)-HRP conjugate (Bio-Rad, 1706516).
[0148] Densitometric analysis was performed using ImageJ software.
[0149] (RNAseq) RNA was extracted from flash frozen tumors using a Qiagen extraction kit and stored at -80°C. Paired-end sequencing was chosen to obtain short reads from the ends of DNA fragments for ultra-high-throughput sequencing. A quality check of the sequencing data was performed before further analysis. All samples contained sequences of 75 nucleotides in length (75nt × 2).
[0150] The RNA-Seq analysis pipeline involves several steps: 1. Lead quality control, 2. Eliminate low-quality leads; 3. Spliced alignment of the leads; 4. Quantitative transcriptome expression analysis.
[0151] (Lead quality control) Quality control is a method used to check the quality of the sequencing of raw data based on statistical and regression graphs and tables, and provide information about possible areas where problems may occur.
[0152] To carry out this step, we used the FastQC tool (available at http: / / www.bioinformatics.babraham.ac.uk / projects / fastqc (Non-Patent Document 21)), a tool for high-throughput sequence data. The FastQC tool returns an html report that allows visualization of information about the sequencing of raw data. The quality value is calculated based on a history called the "phred score".
[0153] The quality value (q) of the phred score uses a mathematical scale that converts the estimated probability of a base misidentification (s) into a logarithmic scale: q = -10 × log10(s).
[0154] Probabilities of misidentification of a base equal to 0.1 (10%), 0.01 (1%), and 0.001 (0.1%) give phred score (q or Q) values of 10, 20, and 30, respectively.
[0155] The FastQC tool provides a summary judgement: pass (green symbol), warning (orange symbol), or fail (red symbol). The phred score is displayed in the "Per Base Sequence Quality" module of the QC report.
[0156] (Removal of low quality leads) To remove reads with low Phred quality scores, we used tools from the NGSQCTool kit.
[0157] (Read Alignment) Using the bioinformatics tool STAR (version 2.4.0d), samples were mapped to the reference Mus Musculus genome (mm10) [4] using standard parameters for paired reads. The reference track was the mm10 assembly obtained from Refseq. The table below shows the percentage of mapped reads for each sample. The average mapping fraction was greater than 93% and the ribosome content was less than 1% for all samples.
[0158] (Quantification of transcriptome expression) Quantification of expressed transcripts was performed for each sequenced sample using Cufflinks. The unit of measurement used in Cufflinks is FPKM (fragments per thousand bases of transcript per million mapped reads), which is meant as a measure of the relative abundance of a transcript / gene in an RNA pool. FPKM is not directly intended to be used for differential expression, but is intended to be human readable and takes into account major technical confounding factors such as millions of reads and gene length.
[0159] (Identification of responders and non-responders) Responders and non-responders were selected based on tumor volume at day 20. The tumor volume at the start of treatment (day 10) averaged approximately 75 mm 3 Based on this tumor volume value, the animals were classified according to the following criteria: - Tumor volume 75mm 3 The following animals were designated as responders (R): - Tumor volume 75mm 3 Animals with more than 10% CI were considered non-responders (NR).
[0160] To identify genes that may be associated with R and NR independent of treatment, all R and NR (including untreated animals) were taken into account.
[0161] To identify specific genes regulated by ITF3756, all animals in this group and the corresponding vehicle control group were considered to identify possible correlations with tumor response.
[0162] To identify specific genes regulated by anti-PD-1 treatment, all animals in this group as well as the isotype control group were considered to identify possible correlations with tumor response.
[0163] Total counts from RNAseq data were used to compare gene expression between R and NR.
[0164] Statistical significance was determined by unpaired t-test using GraphPad software (version 9), and a p-value of 0.05 or less was considered significant.
[0165] (result) (ITF3756 target effect: increased tubulin acetylation) To confirm the inhibition of HDAC6 by ITF3756, spleens of animals were harvested at all sacrifice time points (1 h, 4 h, 18 h, and 24 h) and tubulin acetylation and total tubulin were detected using Western blotting.
[0166] Tumor-bearing animals were sacrificed at various times after the final dose. Spleens were harvested and total spleen cell suspensions were prepared. Total protein extracts were obtained when pelleted cells were lysed and separated by electrophoresis. Tubulin and acetyl-tubulin were detected after Western blotting using specific antibodies.
[0167] Figure 21 shows that tubulin acetylation occurred rapidly. At 1 hour after the final treatment, the animals examined showed a strong increase that was maintained up to 4 hours after the final treatment. A longer wash-out reduced tubulin acetylation, but it was still high and consistent after 18 hours. Results obtained after a 24 hour wash-out showed that tubulin acetylation was still detectable, but not in all animals, since one out of three animals had basal levels of acetyl-tubulin.
[0168] (Anti-PD-1 and ITF375 treatment) As evidenced by both preclinical and clinical studies, anti-PD-1 immunotherapy shows particularly heterogeneous responses. This heterogeneity is dependent on the response of a single subject to immune system stimulation. Consistent with the immune-dependent antitumor activity of ITF3756, the present inventors found similar heterogeneous responses in animals treated with anti-PD-1.
[0169] In both treatments, three groups of animals with different tumor regressions could be identified (Figures 22 and 23): - animals that did not respond to treatment (ITF3756 1 in Figure 22; anti-PD-1 a in Figure 23); - animals with strong or complete tumor shrinkage compared to day 10 (ITF3756 2 in Figure 22; anti-PD-1 b in Figure 23); - Tumor mass is stable or tumor mass is less than 75mm at the start of treatment 3 ) (ITF3756 3 in Figure 22, anti-PD-1 c in Figure 23).
[0170] Correlation analysis showed that in this group, tumor burden was 75 mm 3 Only the following animals were considered:
[0171] Downregulation of MMP9 and upregulation of IRF6 and CD40 correlate with responders. As shown in Table 3, tumor-promoting macrophages with M2 phenotype express specific markers, some of which are robustly downregulated in monocytes treated with ITF3756. MMP9 is one of these genes and is therefore associated with the tumor-promoting phenotype of macrophages.
[0172] We found that downregulation of MMP9 in the tumor microenvironment of CT26-bearing animals was significantly associated with responder animals in the ITF3756 group (Figure 24). This association did not occur when considering all animals or when considering the anti-PD-1 group relative to controls.
[0173] Activation and control of inflammation in the tumor microenvironment is crucial for the appropriate stimulation of antitumor immune responses. We identified two genes involved in the process of remodeling the TME from a noninflammatory and immune-resistant state to an inflammatory and immune-tolerant state. One gene is interferon regulatory factor 6 (IRF6). IRF6 belongs to a family of nine transcription factors that share a highly conserved helix-turn-helix DNA-binding domain and a less conserved protein-binding domain. Most IRFs regulate the expression of interferons after viral infection. IRF6 is well known for its association with craniofacial development, but may be involved in MyD88 signaling together with IRF1 (Honda and Taniguchi, 2006). As shown in Figure 25, ITF3756 up-regulates the expression of IRF6 in human monocytes, and we found that the up-regulation was associated with responder animals treated with ITF3756 (p<0.1).
[0174] Strikingly, animals with the highest IRF6 counts from the RNAseq data experienced complete tumor shrinkage after treatment with ITF3756.
[0175] The role of CD40 has been briefly mentioned previously. Human monocytes treated with ITF3756 showed increased gene expression of CD40, which is directly related to T cell co-stimulation and induction of anti-tumor macrophages. Consistent with this observation, we found that responder mice had significantly higher gene expression of CD40 (Figure 26B). CD40 also showed no correlation with responder mice when considering all animals and those treated with anti-PD-1 antibodies (Figure 26A, Figure 26C).
Claims
1. a) determining in a patient biological sample the expression level of at least one RNA biomarker that is modulated by an HDAC6 inhibitor and is selected from the CD84, RANK / TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204 / MSR1, CD206 / MRC1, MMP9, NBEAL2, LTBP4, ANXA6, FATP1 / SLC27a1, ADA, CD276, CD40 or IRF6 genes; b) comparing said expression level with an expression level in a reference sample; 23. A method for evaluating the effective dose and / or biological activity of an HDAC6 inhibitor, comprising:
2. The method of claim 1, wherein the effective dosage and / or biological activity of the HDAC6 inhibitor is assessed during or after therapeutic treatment of a patient suffering from cancer.
3. c) classifying the patient as responsive or non-responsive to the therapeutic treatment. The method of claim 1 or 2, further comprising:
4. 4. The method of any of claims 1 to 3, wherein the classification of a patient as responsive or non-responsive to a therapeutic treatment is based on whether the expression value of at least one RNA biomarker is above or below a threshold expression value.
5. A method according to any one of claims 1 to 4, characterized in that it is an in vitro or ex vivo method.
6. the expression levels of RNA biomarkers NBEAL2, LTBP4, ANXA6, FATP1 / SCL27a1, CD40 or IRF6 are upregulated by HDAC6 inhibitors; Expression levels of RNA biomarkers CD84, RANK / TNFRSF11a, CXCL3, CXCL2, STAB1, CD163, CD204 / MSR1, CD206 / MRC1, ADA, CD276 or MMP9 are downregulated by HDAC6 inhibitors 6. The method according to any one of claims 1 to 5.
7. The method according to any one of claims 1 to 6, wherein the expression levels of at least the RNA biomarkers STAB1, CD84, CD206 / MRC1, MMP9, CD163, CD40 and IRF6 are assessed, preferably the expression levels of at least the RNA biomarkers MMP9, CD40 and IRF6 are assessed.
8. 8. The method according to any of claims 1 to 7, wherein the HDAC6 inhibitor is selected from tubacin, tubastatin, nextulastat, ACY-1215, ACY-738, ACY-1083, KA2507, T518, SW100 or N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide (ITF3756), preferably said HDAC6 inhibitor is the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide.
9. The method according to any of claims 1 to 8, wherein the biological sample is a tissue sample or a body fluid, preferably said tissue sample is a tumor biopsy or blood cells, preferably said body fluid is blood, serum or plasma.
10. The method according to any of claims 1 to 9, wherein the expression level of at least one RNA biomarker in step a) is detected by RNA sequencing, quantitative RT-PCR, digital PCR, Affymetrix microarray, custom microarray or nanostring technology.
11. The cancers include adrenocortical cell carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma of the skin, bladder cancer, brain tumor, breast cancer, cancer of unknown primary site, cardiac tumor, cervical cancer, bile duct cancer, colon cancer, endometrial cancer, esophageal cancer, intraocular melanoma, fallopian tube cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, testicular cancer, head and neck cancer, hepatocellular carcinoma, islet cell tumor, pancreatic neuroendocrine tumor, Langerhans cell histiocytosis, leukemia, lung cancer (non-small cell, small cell, pleuroblastoma and tracheobronchial tumor), melanoma, Merkel cell carcinoma, mesothelioma, midline duct tumor with NUT gene alteration.
4. The method of claim 3, wherein the cancer is selected from: multiple endocrine neoplasia syndrome, multiple myeloma / plasma cell neoplasm, myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasm, neuroblastoma, ovarian cancer, pancreatic cancer, paraganglioma, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumor, primary peritoneal cancer, prostate cancer, renal cell carcinoma, retinoblastoma, sarcoma, squamous cell carcinoma of the skin, thymoma and thymic carcinoma, thyroid cancer, renal pelvis and ureteral transitional cell carcinoma, uterine cancer, vaginal cancer, vascular tumor, vulvar cancer and Wilms' tumor; preferably, the cancer is melanoma, renal cell carcinoma, non-small cell lung cancer or colorectal cancer.
12. A kit for use in assessing the effective dose and / or biological activity of an HDAC6 inhibitor comprising a multi-well plate and suitable primers and / or probes for determining the expression level of at least one of the RNA biomarkers described in claim 1.
Citation Information
Patent Citations
Histone deacetylase 6 (hac6) biomarker in multiple myeloma
JP2017503492A
Diagnosis and treatment of lupus nephritis
WO2014032899A1
Methods and systems for powering auxiliary devices in photovol taic system
US20120176076A1
Selective HDAC6 inhibitors
WO2018189340A1
